HeyJaredRedFlagHunter
$Reports. I dig deep into filings and fundamentals to uncover red flags and weak narratives-and share the journey along the way.
- Indexed issues, last 90 days
- 2
- Latest publication
- Sep 22, 2026
- Audience
- Checking…
- Earliest in this view
- Aug 17, 2026
Latest issues
[2026] RedFlag Research: FREE News letter - $GRML - Dilution is almost ready! On Promo Pump list (opens the original)
Read excerpt
As of Sept. 22, 2026GRML Stock promotion campaign history<img alt="" class="sizing-normal" height="1078" src="https://substackcdn.com/image/fetch/$s_!qCYk!,w_1456,c_limit,f_auto,q_auto:good,fl_progressive:steep/https%3A%2F%2
CAPR: The FDA Did Not Approve Deramiocel. It Gave Capricor Another Chance (opens the original)
Read excerpt
Capricor Therapeutics ($CAPR) has become one of the more interesting biotech setups in the small-cap space following a sharp move higher after the FDA agreed to review additional 24-month data for Deramiocel, the company’s lead therapy for Duchenne muscular dystrophy.At first glance, the headline sounds extremely bullish.The problem is that the underlying regulatory situation is much more complicated.The FDA did not approve Deramiocel. Instead, this comes after an FDA advisory committee voted 9–
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
No verified audience measurement yet.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.